Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q3 FY19 results · Oct–Dec 2018
Solara Active Pharma Sciences reported revenue from operations of ₹356.23 crore and net profit of ₹22.10 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 356.23 | — | — | 342.33 | +4.1% |
| Other income | 3.88 | — | — | 1.39 | +179.1% |
| Total income | 360.11 | — | — | 343.72 | +4.8% |
| Profit before tax | 22.10 | — | — | 10.18 | +117.1% |
| Net profit for the period | 22.10 | — | — | 8.55 | +158.5% |
| Attributable to shareholders of the company | 22.09 | — | — | 8.53 | +159.0% |
| EPS, basic (₹) | 8.96 | — | — | 3.46 | +159.0% |
| Net margin (%) | 6.2 | — | 2.5 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 347.94 | — | — | 336.41 | +3.4% |
| Other income | 2.52 | — | — | 0.21 | 12x |
| Total income | 350.46 | — | — | 336.62 | +4.1% |
| Profit before tax | 24.39 | — | — | 9.20 | +165.1% |
| Net profit for the period | 24.39 | — | — | 7.57 | +222.2% |
| EPS, basic (₹) | 9.89 | — | — | 1.99 | +397.0% |
| Net margin (%) | 7.0 | — | 2.3 |
Consolidated
- Filed with BSE
- 01 Feb 2019, 15:08 IST
- Board meeting
- 31 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Feb 2019, 15:08 IST
- Board meeting
- 31 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE